Wolfe Research upgraded Silk Road Medical to Peer Perform from Underperform without a price target. While the shares can “grind lower” in short term due to negative estimate revisions, a fresh valuation assessment “should consider takeout scenarios,” the analyst tells investors in a research note. As such, Wolfe sees a more balanced risk/reward at current share levels.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SILK:
- Silk Road Medical price target lowered to $8 from $28 at BofA
- Piper sees finalized NCD as net negative for Silk Road, positive for InspireMD
- Silk Road Medical downgraded to Neutral from Buy at CL King
- Silk Road (NASDAQ:SILK) Plummets as Preliminary Q3 Revenues Disappoint
- Silk Road Medical downgraded to Sell from Buy at Citi